BeiGene, Ltd. (ONC)vsSenti Biosciences Inc (SNTI)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
SNTI
Senti Biosciences Inc
$0.88
+2.30%
HEALTHCARE · Cap: $23.66M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 1580679% more annual revenue ($5.34B vs $338,000). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
SNTI
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for SNTI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : SNTI
The strongest argument for SNTI centers on Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : SNTI
The primary concerns for SNTI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while SNTI is a value play — different risk/reward profiles.
SNTI carries more volatility with a beta of 2.13 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 20/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Senti Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Senti Biosciences Inc (SNTI) is a cutting-edge biotechnology company focused on revolutionizing synthetic biology to develop next-generation cell and gene therapies. Leveraging its proprietary GeneCircuit platform, Senti aims to create programmable therapies designed to address a variety of diseases, including cancer and genetic disorders, thus enhancing the precision of personalized medicine. With a strong development pipeline and strategic partnerships, Senti is well-positioned to lead advancements in engineered cell therapies, providing innovative solutions to address significant unmet medical needs in the biopharmaceutical landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?